Status: Not yet recruiting
A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants
This study is a single-center, open-label, single-dose phase I clinical trial. The trial is divided into four periods: screening, baseline, treatment, and follow-up
Participants needed: 6
Trial details
Phase: Phase 1Age: 18-45Biological sex: MaleType: InterventionalSponsor: Fujian Shengdi Pharmaceutical Co., Ltd.Updated: Jul 2, 2026Locations: 1
Eligibility criteria
Informed consent was obtained voluntarily [+3]
Have a history of drug allergy, specific allergy, or allergic constitution [+11]